JPMorgan Chase & Co. Sells 194,513 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

JPMorgan Chase & Co. decreased its position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 70.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 82,691 shares of the specialty pharmaceutical company's stock after selling 194,513 shares during the period. JPMorgan Chase & Co. owned about 0.26% of Collegium Pharmaceutical worth $2,369,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of COLL. Barclays PLC boosted its holdings in Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after purchasing an additional 45,291 shares during the last quarter. Sanctuary Advisors LLC boosted its holdings in Collegium Pharmaceutical by 10.7% in the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company's stock valued at $695,000 after purchasing an additional 1,731 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after purchasing an additional 64,958 shares during the last quarter. Franklin Resources Inc. boosted its holdings in Collegium Pharmaceutical by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company's stock valued at $1,164,000 after purchasing an additional 3,620 shares during the last quarter. Finally, Amundi boosted its holdings in Collegium Pharmaceutical by 188.3% in the 4th quarter. Amundi now owns 15,568 shares of the specialty pharmaceutical company's stock valued at $446,000 after purchasing an additional 10,168 shares during the last quarter.

Collegium Pharmaceutical Trading Up 0.7 %

Collegium Pharmaceutical stock traded up $0.18 during midday trading on Tuesday, reaching $27.05. The stock had a trading volume of 28,233 shares, compared to its average volume of 441,377. Collegium Pharmaceutical, Inc. has a twelve month low of $23.23 and a twelve month high of $42.29. The stock has a market capitalization of $869.17 million, a PE ratio of 11.69 and a beta of 0.76. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97. The stock's 50-day simple moving average is $28.34 and its 200 day simple moving average is $30.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. Analysts expect that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Piper Sandler decreased their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating for the company in a research report on Tuesday, February 4th. HC Wainwright reiterated a "buy" rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. StockNews.com lowered shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research note on Saturday, April 19th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $46.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Collegium Pharmaceutical presently has an average rating of "Moderate Buy" and a consensus target price of $43.60.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 40,000 shares of the company's stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the sale, the executive vice president now directly owns 154,204 shares of the company's stock, valued at approximately $4,330,048.32. This represents a 20.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Scott Dreyer sold 2,255 shares of the firm's stock in a transaction on Friday, March 14th. The stock was sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the sale, the executive vice president now owns 124,421 shares in the company, valued at $3,732,630. This represents a 1.78 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 81,693 shares of company stock valued at $2,334,994. 2.51% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.